- Home
- ELEV vs RNTX Comparison
ELEV vs RNTX Comparison
Compare ELEV & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELEV
- RNTX
- Stock Information
- Founded
- ELEV 2019
- RNTX 2001
- Country
- ELEV United States
- RNTX United States
- Employees
- ELEV N/A
- RNTX N/A
- Industry
- ELEV Biotechnology: Pharmaceutical Preparations
- RNTX Biotechnology: Pharmaceutical Preparations
- Sector
- ELEV Health Care
- RNTX Health Care
- Exchange
- ELEV Nasdaq
- RNTX Nasdaq
- Market Cap
- ELEV 37.6M
- RNTX 44.2M
- IPO Year
- ELEV 2021
- RNTX N/A
- Fundamental
- Price
- ELEV $0.50
- RNTX $2.02
- Analyst Decision
- ELEV Buy
- RNTX
- Analyst Count
- ELEV 6
- RNTX 0
- Target Price
- ELEV $7.20
- RNTX N/A
- AVG Volume (30 Days)
- ELEV 1.0M
- RNTX 48.0K
- Earning Date
- ELEV 03-06-2025
- RNTX 04-14-2025
- Dividend Yield
- ELEV N/A
- RNTX N/A
- EPS Growth
- ELEV N/A
- RNTX N/A
- EPS
- ELEV N/A
- RNTX N/A
- Revenue
- ELEV N/A
- RNTX N/A
- Revenue This Year
- ELEV N/A
- RNTX N/A
- Revenue Next Year
- ELEV N/A
- RNTX N/A
- P/E Ratio
- ELEV N/A
- RNTX N/A
- Revenue Growth
- ELEV N/A
- RNTX N/A
- 52 Week Low
- ELEV $0.42
- RNTX $1.61
- 52 Week High
- ELEV $5.83
- RNTX $7.42
- Technical
- Relative Strength Index (RSI)
- ELEV 39.41
- RNTX N/A
- Support Level
- ELEV $0.46
- RNTX N/A
- Resistance Level
- ELEV $0.53
- RNTX N/A
- Average True Range (ATR)
- ELEV 0.05
- RNTX 0.00
- MACD
- ELEV -0.00
- RNTX 0.00
- Stochastic Oscillator
- ELEV 36.30
- RNTX 0.00
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03, LTI-01, and others.